

REMARKS

Claims 1-13 are pending.

Sequence identifiers are inserted in the specification, abstract, and claims. Thus, the scope of the claimed invention is not changed because no claim limitation is added or deleted. All of the peptides recited in the claims are directed to a single inventive concept because they are derivatives of the protein FLO (see Table 1).

The paper and computer readable forms of the Sequence Listing do not add new matter, and their contents are the same. It is respectfully submitted that the attached complies with 37 CFR § 1.821 et seq. Otherwise, prompt notice of any defects in the Sequence Listing is earnestly solicited and additional time is requested to comply.

Applicants earnestly solicit an early and favorable examination on the merits. The Examiner is invited to contact the undersigned if any further information is required.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By:


Gary R. Tanidawa
Reg. No. 43,180

901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100